Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System

Cytek Biosciences, Inc. (NASDAQ:CTKB) has announced the launch of its latest innovation, the Cytek Aurora Evo system, marking a significant leap forward in flow cytometry technology. Building on the global success of its flagship Aurora system, the new Aurora Evo introduces high-throughput and automation features designed to accelerate complex cell analysis for researchers worldwide.

Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System

A scientist in a lab analyzing a culture of cells affected by tumor immune evasion.

The Aurora Evo system incorporates Cytek Biosciences, Inc. (NASDAQ:CTKB)’s renowned Full Spectrum Profiling (FSP) technology, which allows scientists to conduct large-scale multicolor experiments with unmatched data quality and flexibility. Key advancements include built-in small particle detection, enabling the study of extracellular vesicles, viruses, and bacteria, and an integrated plate loader for automated, high-efficiency sample processing. Its enhanced instrument standardization ensures consistent, reproducible results across labs and time, while improved electronics and optical design double sample acquisition speed.

Cytek Biosciences, Inc. (NASDAQ:CTKB)’s CTO, Dr. Ming Yan, highlighted the system’s potential to revolutionize immunology and single-cell research, emphasizing its performance, reliability, and ease of use. The Cytek Aurora Evo will debut at CYTO 2025, where live demonstrations will showcase its capabilities to the scientific community.

While we acknowledge the potential of CTKB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than CTKB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.